ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $105.83 Average PT from Brokerages

Posted by on Aug 26th, 2026

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $105.8333.

ANIP has been the topic of a number of recent analyst reports. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Canaccord Genuity Group decreased their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Guggenheim lowered their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Finally, Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th.

View Our Latest Analysis on ANIP

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 2,850 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total transaction of $231,876.00. Following the transaction, the chief financial officer directly owned 174,693 shares in the company, valued at approximately $14,213,022.48. This trade represents a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the sale, the vice president directly owned 74,424 shares in the company, valued at $5,617,523.52. This trade represents a 0.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 18,987 shares of company stock worth $1,546,405 over the last quarter. 8.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. KBC Group NV purchased a new stake in shares of ANI Pharmaceuticals during the first quarter worth about $28,000. Advisors Asset Management Inc. purchased a new stake in ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Hantz Financial Services Inc. grew its stake in ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter valued at about $48,000. Finally, State of Wyoming acquired a new position in shares of ANI Pharmaceuticals in the second quarter valued at about $50,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $75.65 on Wednesday. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals has a 12 month low of $70.15 and a 12 month high of $99.50. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of 16.30 and a beta of 0.44. The firm’s 50-day moving average is $80.05 and its 200 day moving average is $78.80.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same quarter in the previous year, the business earned $1.80 earnings per share. The company’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts predict that ANI Pharmaceuticals will post 7.83 EPS for the current year.

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Featured Stories

Analyst Recommendations for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.